ADARx Prices $446.3 Million Nasdaq IPO, Extending Biotech's Run
ADARx Pharmaceuticals priced a $446.3 million Nasdaq IPO, one of the largest biotech debuts this cycle and the latest sign that the life-sciences listing window has reopened.
Topic
Biotech
Topic
Biotech
Nvidia-Backed Iambic Therapeutics Files for Nasdaq IPO
Iambic Therapeutics, which raised $461.8 million from Nvidia and others, filed Monday for a Nasdaq IPO under ticker IAM to fund t…
NVIDIA, Anthropic and Roche Back Basecamp Research's $140m Series C
S32 leads an oversubscribed US$140m Series C in Basecamp Research, with NVIDIA, Anthropic and Roche's Vice-Chairman backing AI-de…
Jetstream Venture Fund Backs Telomere-Targeting mRNA Startup
Jetstream Venture Fund has invested in Stanford spinout Rejuvenation Technologies, adding a telomere-extending mRNA platform to i…
Kasvu Therapeutics Closes €30 Million Series A Round
Kasvu Therapeutics has raised €30 million in Series A financing, one of the larger early-stage biotech commitments announced via…
Investors Aim to Advance Basecamp Research Toward Clinical Trials
Investors are pushing Basecamp Research to move from protein and biodiversity data infrastructure toward human clinical trials, t…
Iambic Therapeutics Files for IPO as AI Drug Discovery Heats Up
AI drug discovery startup Iambic Therapeutics has filed for an initial public offering, Yahoo Finance reports, testing investor a…
Incyte Gains 22.5% in Three Months, Beating Biotech Peers
Incyte (INCY) is up 22.5% in three months, beating XBI's 11%, after Q2 sales jumped 40.5% to $1.5 billion and management raised F…
Life Sciences Investment Surges as Lab Vacancy Hits Record
Life sciences investment is surging even as lab vacancy hits a record, GlobeSt reports — capital is returning to biotech real est…
EU Clears NewAmsterdam's Cholesterol Pills in First Global Approval
European regulators approved NewAmsterdam Pharma's Ubeslo and Evlarco, its first global nods. Menarini will sell both in Europe,…
Sobi's $75 Million Upfront Buys Innate Pharma Time Until 2028
Innate Pharma closed its lacutamab deal with Sobi, triggering a $75 million upfront payment and a funding runway into Q1 2028 des…